Nausea and Vomiting
60
10
10
33
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
11.7%
7 terminated out of 60 trials
82.5%
-4.0% vs benchmark
33%
20 trials in Phase 3/4
30%
10 of 33 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 33 completed trials
Clinical Trials (60)
Dexmedetomidine and Propofol for Sedation in Cataract Surgery.
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
Domperidone in Treating Patients With Gastrointestinal Disorders
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis
Exploring the Effect of Aromatherapy
Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide
Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
The Impact of Oral Cryotherapy and Chewing Gum Interventions
Prevalence of Hyperemesis Gravidarum
Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer
Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation
Efficacy of Three Antiemetics in Preventing Nausea and Vomiting
Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
the Efficacy and Safety of Ondansetron Oral Soluble Pellicles
Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain
Effect of Inhaled Aromatherapy on Chemo-Induced Nausea Vomiting (NCVI): CINVAROM (Chemotherapy Induced Nausea Vomiting and AROMatherapy)
A Clinical Study to Evaluate Cyclopofol Injection for the Prevention of Postoperative Nausea and Vomiting